Haemonetics Aktie
WKN: 881782 / ISIN: US4050241003
|
09.05.2024 12:14:44
|
Haemonetics Q4 Profit Falls, But Beats Estimates - Update
(RTTNews) - (Adds Outlook)
Looking ahead, for the full year, Haemonetics Corporation (HAE) expects to report adjusted income per share of $4.45 to $4.75, above the analysts' estimate of $4.4 per share.
Revenue is projected to grow 5 percent to 8 percent. Analysts, on average, expect the firm to generate revenue of $1.37 billion, for the year.
Q4 Results:
Haemonetics revealed earnings for fourth quarter that decreased from last year but beat the Street estimates.
The company's bottom line came in at $20.367 million, or $0.40 per share. This compares with $29.383 million, or $0.57 per share, in last year's fourth quarter.
Excluding items, Haemonetics Corp reported adjusted earnings of $46.016 million or $0.90 per share for the period.
Analysts on average had expected the company to earn $0.89 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 12.8% to $343.290 million from $304.416 million last year.
Haemonetics Corp earnings at a glance (GAAP) :
-Earnings (Q4): $20.367 Mln. vs. $29.383 Mln. last year. -EPS (Q4): $0.40 vs. $0.57 last year. -Revenue (Q4): $343.290 Mln vs. $304.416 Mln last year.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Haemonetics Corp.mehr Nachrichten
|
05.11.25 |
Ausblick: Haemonetics verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) | |
|
22.10.25 |
Erste Schätzungen: Haemonetics vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
|
06.08.25 |
Ausblick: Haemonetics zieht Bilanz zum abgelaufenen Quartal (finanzen.net) | |
|
23.07.25 |
Erste Schätzungen: Haemonetics stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) |
Analysen zu Haemonetics Corp.mehr Analysen
Aktien in diesem Artikel
| Haemonetics Corp. | 57,50 | 0,88% |
|